<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7064018\results\search\disease\results.xml">
  <result pre="enveloped, positive-strand RNA viruses. Four human CoVs (HCoVs), the non-severe" exact="acute" post="respiratory syndrome (SARS)-like HCoVs (namely HCoV 229E, NL63, OC43,"/>
  <result pre="positive-strand RNA viruses. Four human CoVs (HCoVs), the non-severe acute" exact="respiratory" post="syndrome (SARS)-like HCoVs (namely HCoV 229E, NL63, OC43, and"/>
  <result pre="RNA viruses. Four human CoVs (HCoVs), the non-severe acute respiratory" exact="syndrome" post="(SARS)-like HCoVs (namely HCoV 229E, NL63, OC43, and HKU1),"/>
  <result pre="are globally endemic and account for a substantial fraction of" exact="upper" post="respiratory tract infections. Non-SARS-like CoV can occasionally produce severe"/>
  <result pre="globally endemic and account for a substantial fraction of upper" exact="respiratory" post="tract infections. Non-SARS-like CoV can occasionally produce severe diseases"/>
  <result pre="epidemics. In contrast, SARS like CoVs (namely SARS-CoV and Middle-East" exact="respiratory" post="syndrome coronavirus, MERS-CoV) can cause intense short-lived fatal outbreaks."/>
  <result pre="In contrast, SARS like CoVs (namely SARS-CoV and Middle-East respiratory" exact="syndrome" post="coronavirus, MERS-CoV) can cause intense short-lived fatal outbreaks. The"/>
  <result pre="speculated that SARS-CoV-2 epidemic is grossly underdiagnosed and that the" exact="infection" post="is silently spreading across the globe with two consequences:"/>
  <result pre="across the globe with two consequences: (i) clusters of severe" exact="infections" post="among frail subjects could haphazardly occur linked to unrecognized"/>
  <result pre="presentations is pivotal for implementing reasonable measures to contain the" exact="infection" post="and to reduce its mortality. Whilst the future evolution"/>
  <result pre="of yet another global epidemic underscores the permanent challenges that" exact="infectious diseases" post="pose and underscores the need for global cooperation and"/>
  <result pre="inter-epidemic periods. Coronavirus MERS-CoV SARS-CoV sARS-CoV-2 COVID-19 epidemiology immunology INTRODUCTION" exact="Infections" post="have been limiting quality of life and longevity throughout"/>
  <result pre="limiting quality of life and longevity throughout human history. Endemic" exact="infections" post="have been associated to a significant number of avoidable"/>
  <result pre="and antibiotics has greatly reduced the probability to succumb to" exact="infectious disease" post="and has improved the confidence of the public in"/>
  <result pre="antibiotics has greatly reduced the probability to succumb to infectious" exact="disease" post="and has improved the confidence of the public in"/>
  <result pre="public in the capacity of mitigating the possible consequences of" exact="infectious" post="outbreaks. Nevertheless, also in recent times, several events produce"/>
  <result pre="diseases. These were the cases of Zika virus (a mild" exact="disease" post="without any mortality excess whose impact is significant for"/>
  <result pre="only (increased rate of birth defect), [1, 2] variant Creutzfeldtâ€&quot;Jakob" exact="disease" post="(â€œmad cow diseaseâ€�) [3] and avian influenza [4]. The"/>
  <result pre="[1, 2] variant Creutzfeldtâ€&quot;Jakob disease (â€œmad cow diseaseâ€�) [3] and" exact="avian influenza" post="[4]. The latter two diseases are both zoonotic infections"/>
  <result pre="avian influenza [4]. The latter two diseases are both zoonotic" exact="infections" post="without any pandemic potential due to the lack of"/>
  <result pre="and therapeutic interventions Ebola outbreak (2014-2016) [5]. The study of" exact="respiratory" post="viral infections has recently changed due to the standardized"/>
  <result pre="therapeutic interventions Ebola outbreak (2014-2016) [5]. The study of respiratory" exact="viral" post="infections has recently changed due to the standardized use"/>
  <result pre="interventions Ebola outbreak (2014-2016) [5]. The study of respiratory viral" exact="infections" post="has recently changed due to the standardized use of"/>
  <result pre="available tests allow for the simultaneous detection of 20 common" exact="viral" post="and bacterial pathogens within one hour, but tests leading"/>
  <result pre="allow for the simultaneous detection of 20 common viral and" exact="bacterial" post="pathogens within one hour, but tests leading to the"/>
  <result pre="tests leading to the identification of ever larger panels of" exact="infectious" post="agents are under development [6]. PATHOGENIC HUMAN CORONAVIRUSES Among"/>
  <result pre="[6]. PATHOGENIC HUMAN CORONAVIRUSES Among the causative agents of human" exact="respiratory" post="tract infections are coronaviruses (CoVs) which are enveloped, single"/>
  <result pre="HUMAN CORONAVIRUSES Among the causative agents of human respiratory tract" exact="infections" post="are coronaviruses (CoVs) which are enveloped, single positive-strand RNA"/>
  <result pre="the large subfamily Coronavirinae which infect birds and mammals. The" exact="viral" post="RNA is the largest genome known and it is"/>
  <result pre="229E, NL63, OC43, and HKU1), are known as non- severe" exact="acute" post="respiratory syndrome (SARS)-like CoVs. They cause mild diseases and"/>
  <result pre="NL63, OC43, and HKU1), are known as non- severe acute" exact="respiratory" post="syndrome (SARS)-like CoVs. They cause mild diseases and are"/>
  <result pre="OC43, and HKU1), are known as non- severe acute respiratory" exact="syndrome" post="(SARS)-like CoVs. They cause mild diseases and are globally"/>
  <result pre="named SARS-CoV-1) discovered in November, 2002 [9], the Middle East" exact="respiratory" post="syndrome (MERS) coronavirus (MERS-CoV) in June, 2012 [10]; and"/>
  <result pre="SARS-CoV-1) discovered in November, 2002 [9], the Middle East respiratory" exact="syndrome" post="(MERS) coronavirus (MERS-CoV) in June, 2012 [10]; and SARS-CoV-2,"/>
  <result pre="sequencing of clinical samples from a cluster of patients with" exact="pneumonia" post="in Wuhan, China [11]. The disease caused by SARS-CoV-2"/>
  <result pre="cluster of patients with pneumonia in Wuhan, China [11]. The" exact="disease" post="caused by SARS-CoV-2 is named Coronavirus Diseases-2019 (COVID-19) All"/>
  <result pre="MERS-CoV was first isolated from a lung sample of an" exact="adult" post="patient who died of pneumonia at the Al-Fakieh hospital"/>
  <result pre="a lung sample of an adult patient who died of" exact="pneumonia" post="at the Al-Fakieh hospital in Jeddah, Saudi Arabia. MERS-CoV."/>
  <result pre="Dromedaries and camels are implicated as the zoonotic source of" exact="infection" post="[14]. MERS-CoV continues to circulate and cause human disease"/>
  <result pre="of infection [14]. MERS-CoV continues to circulate and cause human" exact="disease" post="with intermittent community clusters, and nosocomial outbreaks in the"/>
  <result pre="outbreaks in the Middle East. MERS-CoV continues to cause human" exact="disease" post="and as of Feb 29, 2020, there have been"/>
  <result pre="(2106 cases, 780 deaths) [15]. CLINICAL CHARACTERISTICS OF HUMAN CORONAVIRUS" exact="INFECTIONS" post="The clinical features of low pathogenic non-SARS CoV infections"/>
  <result pre="CORONAVIRUS INFECTIONS The clinical features of low pathogenic non-SARS CoV" exact="infections" post="are undistinguishable from those found in patients with influenza"/>
  <result pre="found in patients with influenza virus (up to 61,000 lethal" exact="infections" post="per year only in the US according to the"/>
  <result pre="year only in the US according to the Centers for" exact="Disease" post="Control and Prevention, [16]). As with influenza and respiratory"/>
  <result pre="for Disease Control and Prevention, [16]). As with influenza and" exact="respiratory" post="syncytial virus (RSV) infections, the majority of CoV infections"/>
  <result pre="and respiratory syncytial virus (RSV) infections, the majority of CoV" exact="infections" post="usually lead to an asymptomatic or mild flu-like syndrome."/>
  <result pre="asymptomatic or mild flu-like syndrome. Hence, without molecular diagnosis, these" exact="viral" post="respiratory diseases, which all follow a seasonal pattern with"/>
  <result pre="or mild flu-like syndrome. Hence, without molecular diagnosis, these viral" exact="respiratory" post="diseases, which all follow a seasonal pattern with a"/>
  <result pre="winter, are classed together as â€œfluâ€�, irrespective of their exact" exact="infectious" post="etiology. Non-SARS like CoV account for up to 20%"/>
  <result pre="etiology. Non-SARS like CoV account for up to 20% of" exact="upper" post="respiratory tract infections in adults [17] (Table 1). However,"/>
  <result pre="Non-SARS like CoV account for up to 20% of upper" exact="respiratory" post="tract infections in adults [17] (Table 1). However, non-SARS-like"/>
  <result pre="CoV account for up to 20% of upper respiratory tract" exact="infections" post="in adults [17] (Table 1). However, non-SARS-like CoVs can"/>
  <result pre="1). However, non-SARS-like CoVs can be occasionally associated with severe" exact="acute" post="respiratory illness (SARI) in the elderly, diabetics, and those"/>
  <result pre="However, non-SARS-like CoVs can be occasionally associated with severe acute" exact="respiratory" post="illness (SARI) in the elderly, diabetics, and those with"/>
  <result pre="are generally associated with more severe clinical presentations. TABLE 1." exact="Respiratory" post="tract infections with non-SARS coronaviruses. Country Number of cases"/>
  <result pre="associated with more severe clinical presentations. TABLE 1. Respiratory tract" exact="infections" post="with non-SARS coronaviruses. Country Number of cases investigated Percentage"/>
  <result pre="by the mass news and social media than any other" exact="disease" post="[20]. The rapid spread and ensuing public health control"/>
  <result pre="reports from Saudi Arabia describe transmission of silent or subclinical" exact="secondary" post="infections after exposure to patients with MERS-CoV infections, some"/>
  <result pre="from Saudi Arabia describe transmission of silent or subclinical secondary" exact="infections" post="after exposure to patients with MERS-CoV infections, some being"/>
  <result pre="healthy individuals who were household contacts carrying MERS-CoV in their" exact="upper" post="respiratory tract at low levels low amounts indicating that"/>
  <result pre="individuals who were household contacts carrying MERS-CoV in their upper" exact="respiratory" post="tract at low levels low amounts indicating that MERS-CoV"/>
  <result pre="bats, and other animals have been proposed, the source of" exact="primary" post="SARS-CoV-2 transmission to humans remains unknown. The main clinical"/>
  <result pre="to humans remains unknown. The main clinical features of COVID-19" exact="disease" post="appear similar to other CoVs infections of humans. SARS-CoV-2"/>
  <result pre="clinical features of COVID-19 disease appear similar to other CoVs" exact="infections" post="of humans. SARS-CoV-2 is generally associated with upper respiratory"/>
  <result pre="other CoVs infections of humans. SARS-CoV-2 is generally associated with" exact="upper" post="respiratory tract and high viral loads in upper respiratory"/>
  <result pre="CoVs infections of humans. SARS-CoV-2 is generally associated with upper" exact="respiratory" post="tract and high viral loads in upper respiratory tract"/>
  <result pre="SARS-CoV-2 is generally associated with upper respiratory tract and high" exact="viral" post="loads in upper respiratory tract secretions. This may evolve"/>
  <result pre="associated with upper respiratory tract and high viral loads in" exact="upper" post="respiratory tract secretions. This may evolve and progress towards"/>
  <result pre="with upper respiratory tract and high viral loads in upper" exact="respiratory" post="tract secretions. This may evolve and progress towards SARI"/>
  <result pre="evolve and progress towards SARI and in some cases to" exact="acute" post="respiratory distress syndrome (ARDS), in the elderly, patients with"/>
  <result pre="and progress towards SARI and in some cases to acute" exact="respiratory" post="distress syndrome (ARDS), in the elderly, patients with comorbidities"/>
  <result pre="towards SARI and in some cases to acute respiratory distress" exact="syndrome" post="(ARDS), in the elderly, patients with comorbidities and immunosuppression"/>
  <result pre="the role of asymptomatic SARS-CoV-2 infected individuals in disseminating the" exact="infection" post="(and sometimes to act as so-called â€˜superspreaders') remains to"/>
  <result pre="The SARS epidemic in 2002-2003 emphasized that correct management of" exact="symptomatic" post="cases within and outside hospital was crucial for containing"/>
  <result pre="of SARS into Vancouver (British Columbia, Canada), resulted in stopping" exact="secondary" post="transmissions within the city. In contrast, inadequate application of"/>
  <result pre="secondary transmissions within the city. In contrast, inadequate application of" exact="infection" post="control measures in Toronto (Ontario, Canada) and Taipei (Taiwan)"/>
  <result pre="information from Italy suggests that a large proportion of the" exact="primary" post="clusters reported form Lombardy were actually linked to an"/>
  <result pre="Lombardy were actually linked to an emergency department where a" exact="symptomatic" post="case was received on February 16th (currently the whole"/>
  <result pre="spread of CoVs within healthcare services and of causing severe" exact="disease" post="in susceptible individuals is not only restricted to SARS-CoV-1,"/>
  <result pre="analysis of the endemic non-SARS-like CoVs reveals a similar pattern." exact="Severe" post="infections with CoV-229E have been described in association with"/>
  <result pre="of the endemic non-SARS-like CoVs reveals a similar pattern. Severe" exact="infections" post="with CoV-229E have been described in association with an"/>
  <result pre="have been described in association with an outbreak in a" exact="neonatal" post="intensive care unit (University Hospital, Brest, France) [32]. CoV-NL63"/>
  <result pre="of SARI in a long-term care facility with a 27.7%" exact="infection" post="rate and 1.5% lethality in Baton Rouge, Louisiana, USA"/>
  <result pre="on hospital outbreaks of CoV-OC43 and CoV-HKU1 are scanty, and" exact="infections" post="by these CoVs resulting in SARI are typically seen"/>
  <result pre="propensity for nosocomial spreading and the dominant role played by" exact="symptomatic" post="patients in the spreading of the infection are supported"/>
  <result pre="role played by symptomatic patients in the spreading of the" exact="infection" post="are supported by basic virology. CoVs, such as CoV-NL63,"/>
  <result pre="use a specific receptor, angiotensin converting enzyme 2 (ACE2), a" exact="type I" post="transmembrane metallocarboxypeptidase with homology to ACE, which is expressed"/>
  <result pre="with homology to ACE, which is expressed in human airway" exact="epithelial" post="cells, lung parenchyma, heart, lung, kidney and intestinal tract"/>
  <result pre="tract [36, 37]. Since ACE2 is primarily expressed in the" exact="lower" post="respiratory tract, meaning that subjects exposed to index cases"/>
  <result pre="[36, 37]. Since ACE2 is primarily expressed in the lower" exact="respiratory" post="tract, meaning that subjects exposed to index cases producing"/>
  <result pre="producing virus-containing aerosol (e.g. intubated patients or patients with high" exact="viral" post="load and severe cough) are the most likely to"/>
  <result pre="load and severe cough) are the most likely to develop" exact="primary" post="(severe) pulmonary infection [17, 38â€&quot;40]. PATHOGENESIS, DISEASE SEVERITY AND"/>
  <result pre="severe cough) are the most likely to develop primary (severe)" exact="pulmonary" post="infection [17, 38â€&quot;40]. PATHOGENESIS, DISEASE SEVERITY AND EPIDEMIC SPREAD"/>
  <result pre="cough) are the most likely to develop primary (severe) pulmonary" exact="infection" post="[17, 38â€&quot;40]. PATHOGENESIS, DISEASE SEVERITY AND EPIDEMIC SPREAD Epidemiological"/>
  <result pre="potentially higher than those reported for endemic human non-SARS CoV" exact="infections" post="[42]. During the first two months of the current"/>
  <result pre="or even cross-immunity for other CoV species [43]. Unlike other" exact="respiratory" post="diseases that have a quadratic (&quot;U&quot;-shaped) lethality curve (killing"/>
  <result pre="even related to the activation of exaggerated immune mechanism, causing" exact="uncontrolled" post="inflammation as this has been suspected for SARS and"/>
  <result pre="might explain observed the geographic discrepancies of severe cases and" exact="lower" post="mortality than SARS of MERS [46]. SARS-CoV-1 caused an"/>
  <result pre="lymphocyte-mediated immune responses is pivotal for controlling MERS-CoV and SARS-CoV" exact="infections" post="[51, 52]. Evidence in animals are confirmed by observational"/>
  <result pre="experiments to investigate immune responses against HLA class-I and class-II-restricted" exact="viral" post="epitopes mediated by CD8+ and CD4+ T lymphocytes, respectively,"/>
  <result pre="high chances to be locally present in, or close to," exact="respiratory" post="epithelia but have comparatively low chances to be detectable"/>
  <result pre="epithelia but have comparatively low chances to be detectable in" exact="peripheral" post="blood [57â€&quot;59]. It is well possible that the exclusive"/>
  <result pre="responses. Thus, it is possible that the actual incidence of" exact="infections" post="with SARS-CoV-2 is much higher than the observed number"/>
  <result pre="scenario may have two consequences. First, over the forthcoming months," exact="symptomatic" post="cases could haphazardly occur either as (apparently) sporadic cases"/>
  <result pre="[60, 61]. In this context, it becomes plausible that, after" exact="infection" post="by SARS-CoV-2, a sort of race decides the course"/>
  <result pre="in the best-case-scenario without any (or mild) clinical signs of" exact="infection" post="â€&quot; or the virus causes a state of immunosuppression"/>
  <result pre="(Fig. 1A). In this context, the initial dose of the" exact="viral" post="inoculum leading to infection may have a decisive impact"/>
  <result pre="context, the initial dose of the viral inoculum leading to" exact="infection" post="may have a decisive impact on all subsequent events"/>
  <result pre="cross-reactive CoVs might influence the outcome of the race between" exact="viral" post="replication and T-lymphocyte responses as well. Hence, it is"/>
  <result pre="to be demonstrated, that SARS-CoV-2 transmission from indolent or mildly" exact="symptomatic" post="persons to naive individuals generally occurs at a relatively"/>
  <result pre="persons to naive individuals generally occurs at a relatively low" exact="viral" post="load (lower than if the infection stems from severely"/>
  <result pre="at a relatively low viral load (lower than if the" exact="infection" post="stems from severely affected patients), which then might have"/>
  <result pre="probabilities to induce immunity instead of severe and sometimes lethal" exact="infection" post="(Fig. 1C). That said, current evidence suggests that the"/>
  <result pre="said, current evidence suggests that the most solid predictors of" exact="disease" post="severity after infection with SARS-COV-2 are the patient's age"/>
  <result pre="suggests that the most solid predictors of disease severity after" exact="infection" post="with SARS-COV-2 are the patient's age and the concurrence"/>
  <result pre="specific co-morbidities. In contrast, there is no proof (yet) that" exact="infection" post="by a pauci-symptomatic person would result in a milder"/>
  <result pre="tends to suppress the immune response. Therefore, the outcome of" exact="infection" post="is determined by the kinetics of the immune response"/>
  <result pre="determined by the kinetics of the immune response leading to" exact="viral" post="elimination versus viral replication leading to immunosuppression. (B) Hypothetical"/>
  <result pre="kinetics of the immune response leading to viral elimination versus" exact="viral" post="replication leading to immunosuppression. (B) Hypothetical effect of the"/>
  <result pre="effect of the initial contagion on the course of the" exact="infection" post="caused by SARS-CoV-2. A low-level contagion would favor an"/>
  <result pre="of the infected person. Transmission of a large number of" exact="viral" post="particles would tend to cause multifocal respiratory infection leading"/>
  <result pre="large number of viral particles would tend to cause multifocal" exact="respiratory" post="infection leading to immunosuppression and severe illness and possibly"/>
  <result pre="number of viral particles would tend to cause multifocal respiratory" exact="infection" post="leading to immunosuppression and severe illness and possibly death."/>
  <result pre="of SARS-CoV-2. Indolent carriers would tend to transmit a low" exact="viral" post="load to their contacts, leading to indolent disease and"/>
  <result pre="a low viral load to their contacts, leading to indolent" exact="disease" post="and antiviral immune responses in immunocompetent individuals. This mode"/>
  <result pre="it attains a large fraction of the population. In contrast," exact="symptomatic" post="carriers might transmit larger amounts of viral particles with"/>
  <result pre="population. In contrast, symptomatic carriers might transmit larger amounts of" exact="viral" post="particles with a higher probability of leading to severe"/>
  <result pre="global spread and maintaining global health security. Implementation of collective" exact="infection" post="control measures (e.g. social isolation, distancing or quarantine of"/>
  <result pre="of health services. It is important to note that collective" exact="infection" post="control measures can actually reduce the frequency of infection,"/>
  <result pre="of a prolongation of the epidemic period. Thus, in the" exact="absence of" post="an effective vaccine and effective antiviral drugs, all infection"/>
  <result pre="absence of an effective vaccine and effective antiviral drugs, all" exact="infection" post="control measures should be properly undertaken with the aim"/>
  <result pre="interventions is to preserve the healthcare system. The implementation of" exact="infection" post="control measures within hospitals is crucial to protect healthcare"/>
  <result pre="receive the most appropriate treatment. Currently, most of the SARS-CoV-2" exact="infections" post="need no therapy, and overtreatment of patients without current"/>
  <result pre="SARS-CoV-2 replication including chloroquine are clinical efficient against declared SARS-CoV-2" exact="infection" post="[62â€&quot;64]. If these findings are confirmed, chloroquine might be"/>
  <result pre="with existing medical problems) that have a high risk of" exact="viral" post="exposure. Chloroquine has been used for decades for the"/>
  <result pre="been used for decades for the prevention and treatment of" exact="malaria" post="with minimal side effects and at a low cost,"/>
  <result pre="that is typical of any global epidemic event. Again, exaggerated" exact="infection" post="control measures may be pernicious as they increase frustration"/>
  <result pre="susceptible individuals with comorbidities. Moreover, the hype and scaremongering going" exact="viral" post="on mass news and social media, predicting the dawn"/>
  <result pre="COVID-19 epidemic is resulting in a social rather than a" exact="viral" post="catastrophe. Whilst the future evolution of this epidemic remains"/>
  <result pre="of yet another global epidemic unveils the permanent challenge that" exact="infectious diseases" post="represent for humankind and underscores the need for global"/>
  <result pre="la Recherche (ANR, fr: National Agency for Research), (reference: MÃ©diterranÃ©e" exact="Infection" post="10-IAHU-03). Alimuddin Zumla and Giuseppe Ippolito are co-principal investigators"/>
  <result pre="co-principal investigators of the Pan-African Network on Emerging and Re-emerging" exact="Infections" post="(PANDORA-ID-NET), funded by the European &amp;amp; Developing Countries Clinical"/>
  <result pre="Linea 1. GK is supported by the Ligue contre le" exact="Cancer" post="(Ã©quipe labellisÃ©e); Agence National de la Recherche (ANR) â€&quot;"/>
  <result pre="Diseases; AMMICa US23/CNRS UMS3655; Association pour la recherche sur le" exact="cancer" post="(ARC); Association â€œLe Cancer du Sein, Parlons-en!â€�; CancÃ©ropÃ´le Ile-de-France;"/>
  <result pre="Association pour la recherche sur le cancer (ARC); Association â€œLe" exact="Cancer" post="du Sein, Parlons-en!â€�; CancÃ©ropÃ´le Ile-de-France; Chancelerie des universitÃ©s de"/>
  <result pre="(FRM); a donation by Elior; European Research Area Network on" exact="Cardiovascular Diseases" post="(ERA-CVD, MINOTAUR); Gustave Roussy Odyssea, the European Union Horizon"/>
  <result pre="a donation by Elior; European Research Area Network on Cardiovascular" exact="Diseases" post="(ERA-CVD, MINOTAUR); Gustave Roussy Odyssea, the European Union Horizon"/>
  <result pre="High-end Foreign Expert Program in China (GDW20171100085), Institut National du" exact="Cancer" post="(INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation;"/>
  <result pre="Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and" exact="Tumor" post="Immune Elimination (SOCRATE); and the SIRIC Cancer Research and"/>
  <result pre="DNA Repair and Tumor Immune Elimination (SOCRATE); and the SIRIC" exact="Cancer" post="Research and Personalized Medicine (CARPEM). References REFERENCES 1MacciocchiDLaniniSVairoFZumlaAFigueiredoLTLauriaFNStradaGBrouquiPPuroVKrishnaSKremsnerPScognamiglioPKohlerCet al.Short-term"/>
  <result pre="Infect Dis2012121291491510.1016/s1473-3099(12)70304-323316491 4SuttonTCThe Pandemic Threat of Emerging H5 and H7" exact="Avian" post="Influenza Viruses.Viruses201810946110.3390/v10090461 5collab: WHO.Ebola 2014-2016.Available at: https://www.who.int/csr/disease/ebola/en/. [Accessed: 29.02.2020]"/>
  <result pre="6Le-VietNLeVNChungHPhanDTPhanQDCaoTVAbatCRaoult D and ParolaPProspective case-control analysis of the aetiologies of" exact="acute" post="undifferentiated fever in Vietnam.Emerg Microbes Infect20198133935210.1080/22221751.2019.158053930866787 7ToKKHungIFChan JF and"/>
  <result pre="Animal-to-Human Transmitted Human Coronaviruses: SARSâ€&quot;CoV-2 and SARS-CoV.Viruses2020122E24410.3390/v1202024432098422 9collab: WHO.SARS (severe" exact="acute" post="respiratory syndrome).Available at: https://www.who.int/ith/diseases/sars/en/ [Accessed: 29.02.2020] 10ZakiAMvan BoheemenSBestebroerTMOsterhaus AD"/>
  <result pre="Transmitted Human Coronaviruses: SARSâ€&quot;CoV-2 and SARS-CoV.Viruses2020122E24410.3390/v1202024432098422 9collab: WHO.SARS (severe acute" exact="respiratory" post="syndrome).Available at: https://www.who.int/ith/diseases/sars/en/ [Accessed: 29.02.2020] 10ZakiAMvan BoheemenSBestebroerTMOsterhaus AD and"/>
  <result pre="and FouchierRAIsolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi Arabia.N Engl J Med2012367191814182010.1056/nejmoa121172123075143 11collab: WHO.Coronavirus disease"/>
  <result pre="with pneumonia in Saudi Arabia.N Engl J Med2012367191814182010.1056/nejmoa121172123075143 11collab: WHO.Coronavirus" exact="disease" post="(COVID-19) outbreak.Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 [Accessed: 29.02.2020] 12PeirisJSYuenKYOsterhaus AD and"/>
  <result pre="outbreak.Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 [Accessed: 29.02.2020] 12PeirisJSYuenKYOsterhaus AD and StohrKThe severe" exact="acute" post="respiratory syndrome.N Engl J Med2003349252431244110.1056/NEJMra03249814681510 13HijawiBAbdallatMSayaydehAAlqasrawiSHaddadinAJaarourNAlsheikh S and AlsanouriTNovel"/>
  <result pre="at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 [Accessed: 29.02.2020] 12PeirisJSYuenKYOsterhaus AD and StohrKThe severe acute" exact="respiratory" post="syndrome.N Engl J Med2003349252431244110.1056/NEJMra03249814681510 13HijawiBAbdallatMSayaydehAAlqasrawiSHaddadinAJaarourNAlsheikh S and AlsanouriTNovel coronavirus"/>
  <result pre="respiratory syndrome.N Engl J Med2003349252431244110.1056/NEJMra03249814681510 13HijawiBAbdallatMSayaydehAAlqasrawiSHaddadinAJaarourNAlsheikh S and AlsanouriTNovel coronavirus" exact="infections" post="in Jordan, April 2012: epidemiological findings from a retrospective"/>
  <result pre="transmission of MERS coronavirus.N Engl J Med2014370262499250510.1056/nejmc140984724896817 15collab: WHO.Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV).Available at: https://www.who.int/emergencies/mers-cov/en/ [Accessed: 29.02.2020] 16collab: CDC.Coronavirus"/>
  <result pre="of MERS coronavirus.N Engl J Med2014370262499250510.1056/nejmc140984724896817 15collab: WHO.Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV).Available at: https://www.who.int/emergencies/mers-cov/en/ [Accessed: 29.02.2020] 16collab: CDC.Coronavirus Disease"/>
  <result pre="respiratory syndrome coronavirus (MERS-CoV).Available at: https://www.who.int/emergencies/mers-cov/en/ [Accessed: 29.02.2020] 16collab: CDC.Coronavirus" exact="Disease" post="2019.Available at: https://www.cdc.gov[Accessed: 29.02.2020] 17PaulesCIMarston HD and FauciASCoronavirus Infections-More"/>
  <result pre="Infections-More Than Just the Common Cold.JAMA2020323870710.1001/jama.2020.0757 18HuiDSMemish ZA and ZumlaASevere" exact="acute" post="respiratory syndrome vs. the Middle East respiratory syndrome.Curr Opin"/>
  <result pre="Than Just the Common Cold.JAMA2020323870710.1001/jama.2020.0757 18HuiDSMemish ZA and ZumlaASevere acute" exact="respiratory" post="syndrome vs. the Middle East respiratory syndrome.Curr Opin Pulm"/>
  <result pre="Just the Common Cold.JAMA2020323870710.1001/jama.2020.0757 18HuiDSMemish ZA and ZumlaASevere acute respiratory" exact="syndrome" post="vs. the Middle East respiratory syndrome.Curr Opin Pulm Med201420323324110.1097/mcp.000000000000004624626235"/>
  <result pre="ZA and ZumlaASevere acute respiratory syndrome vs. the Middle East" exact="respiratory" post="syndrome.Curr Opin Pulm Med201420323324110.1097/mcp.000000000000004624626235 19GuanWJNiZYHuYLiangWHOuCQHeJXLiuLShanHLeiCLHuiDSCDuBLiLJZengGet al.Clinical Characteristics of Coronavirus"/>
  <result pre="respiratory syndrome.Curr Opin Pulm Med201420323324110.1097/mcp.000000000000004624626235 19GuanWJNiZYHuYLiangWHOuCQHeJXLiuLShanHLeiCLHuiDSCDuBLiLJZengGet al.Clinical Characteristics of Coronavirus" exact="Disease" post="2019 in China.N Engl J Med.202010.1056/NEJMoa2002032 20IppolitoGHuiDSNtoumiFMaeurer M and"/>
  <result pre="MERS to South Korea and China.Lancet Respir Med20153750951010.1016/s2213-2600(15)00238-626050550 24collab: WHO.Coronavirus" exact="disease" post="(COVID-19) outbreak.Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 [Accessed: 29.02.2020)] 25BaiYYaoLWeiTTianFJinDYChen L and"/>
  <result pre="and WangMPresumed Asymptomatic Carrier Transmission of COVID-19.JAMA.202010.1001/jama.2020.2565 26collab: Novel Coronavirus" exact="Pneumonia" post="Emergency Response Epidemiology TeamThe epidemiological characteristics of an outbreak"/>
  <result pre="Xing Bing Xue Za Zhi202041214515110.3760/cma.j.issn.0254-6450.2020.02.00332064853 27HuiDSAzharEIKimYJMemishZAOh MD and ZumlaAMiddle East" exact="respiratory" post="syndrome coronavirus: risk factors and determinants of primary, household,"/>
  <result pre="Bing Xue Za Zhi202041214515110.3760/cma.j.issn.0254-6450.2020.02.00332064853 27HuiDSAzharEIKimYJMemishZAOh MD and ZumlaAMiddle East respiratory" exact="syndrome" post="coronavirus: risk factors and determinants of primary, household, and"/>
  <result pre="determinants of primary, household, and nosocomial transmission.Lancet Infect Dis2018188e217e22710.1016/s1473-3099(18)30127-029680581 28HuiDSCZumlaASevere" exact="Acute" post="Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features.Infect Dis Clin"/>
  <result pre="of primary, household, and nosocomial transmission.Lancet Infect Dis2018188e217e22710.1016/s1473-3099(18)30127-029680581 28HuiDSCZumlaASevere Acute" exact="Respiratory" post="Syndrome: Historical, Epidemiologic, and Clinical Features.Infect Dis Clin North"/>
  <result pre="Features.Infect Dis Clin North Am201933486988910.1016/j.idc.2019.07.00131668196 29ZumlaAHui DS and PerlmanSMiddle East" exact="respiratory" post="syndrome.Lancet20153869997995100710.1016/S0140-6736(15)60454-826049252 30DayMCovid-19: surge in cases in Italy and South"/>
  <result pre="C and SizunJOutbreaks of human coronavirus in a pediatric and" exact="neonatal" post="intensive care unit.Eur J Pediatr2008167121427143410.1007/s00431-008-0687-018335238 33HandJRoseEBSalinasALuXSakthivelSKSchneider E and WatsonJTSevere"/>
  <result pre="neonatal intensive care unit.Eur J Pediatr2008167121427143410.1007/s00431-008-0687-018335238 33HandJRoseEBSalinasALuXSakthivelSKSchneider E and WatsonJTSevere" exact="Respiratory" post="Illness Outbreak Associated with Human Coronavirus NL63 in a"/>
  <result pre="Pat YuenGBrottetERoquebert B and MartinetOIntensive care admission for Coronavirus OC43" exact="respiratory" post="tract infections.Med Mal Infect201848214114410.1016/j.medmal.2018.01.00129402475 35KanwarASelvaraju S and EsperFHuman Coronavirus-HKU1"/>
  <result pre="respiratory tract infections.Med Mal Infect201848214114410.1016/j.medmal.2018.01.00129402475 35KanwarASelvaraju S and EsperFHuman Coronavirus-HKU1" exact="Infection" post="Among Adults in Cleveland, Ohio.Open Forum Infect Dis201742ofx05210.1093/ofid/ofx05228616442 36LiWMooreMJVasilievaNSuiJWongSKBerneMASomasundaranMSullivanJLLuzuriagaKGreenoughTCChoe"/>
  <result pre="and FarzanMThe S proteins of human coronavirus NL63 and severe" exact="acute" post="respiratory syndrome coronavirus bind overlapping regions of ACE2.Virology2007367236737410.1016/j.virol.2007.04.03517631932 39CaoYLiLFengZWanSHuangPSunXWenFHuangXNing"/>
  <result pre="FarzanMThe S proteins of human coronavirus NL63 and severe acute" exact="respiratory" post="syndrome coronavirus bind overlapping regions of ACE2.Virology2007367236737410.1016/j.virol.2007.04.03517631932 39CaoYLiLFengZWanSHuangPSunXWenFHuangXNing G"/>
  <result pre="S proteins of human coronavirus NL63 and severe acute respiratory" exact="syndrome" post="coronavirus bind overlapping regions of ACE2.Virology2007367236737410.1016/j.virol.2007.04.03517631932 39CaoYLiLFengZWanSHuangPSunXWenFHuangXNing G and"/>
  <result pre="Travel Med.202010.1093/jtm/taaa030 42WuZMcGooganJMCharacteristics of and Important Lessons From the Coronavirus" exact="Disease" post="2019 (COVID-19) Outbreak in China: Summary of a Report"/>
  <result pre="a Report of 72314 Cases From the Chinese Center for" exact="Disease" post="Control and Prevention.JAMA.202010.1001/jama.2020.2648 43SeveranceEGBossisIDickersonFBStallingsCROrigoniAESullensAYolken RH and ViscidiRPDevelopment of a"/>
  <result pre="II DR 0301 genotypes are associated with resistance to severe" exact="acute" post="respiratory syndrome (SARS) infection.Viral Immunol201124542142610.1089/vim.2011.002421958371 45NewtonAHCardani A and BracialeTJThe"/>
  <result pre="DR 0301 genotypes are associated with resistance to severe acute" exact="respiratory" post="syndrome (SARS) infection.Viral Immunol201124542142610.1089/vim.2011.002421958371 45NewtonAHCardani A and BracialeTJThe host"/>
  <result pre="0301 genotypes are associated with resistance to severe acute respiratory" exact="syndrome" post="(SARS) infection.Viral Immunol201124542142610.1089/vim.2011.002421958371 45NewtonAHCardani A and BracialeTJThe host immune"/>
  <result pre="infection.Viral Immunol201124542142610.1089/vim.2011.002421958371 45NewtonAHCardani A and BracialeTJThe host immune response in" exact="respiratory" post="virus infection: balancing virus clearance and immunopathology.Semin Immunopathol201638447148210.1007/s00281-016-0558-026965109 46TetroJAIs"/>
  <result pre="SullivanJSInfluence of HLA gene polymorphisms on susceptibility and outcome post" exact="infection" post="with the SARS-CoV virus.Virol Sin201429212813010.1007/s12250-014-3398-x24643938 51ZhaoJZhaoJMangalamAKChannappanavarRFettCMeyerholzDKAgnihothramSBaricRSDavid CS and PerlmanSAirway"/>
  <result pre="PerlmanSAirway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging" exact="Respiratory" post="Coronaviruses.Immunity20164461379139110.1016/j.immuni.2016.05.00627287409 52ColemanCMSiskJMHalaszGZhongJBeckSEMatthewsKLVenkataramanTRajagopalanSKyratsous CA and FriemanMBCD8+ T Cells and Macrophages"/>
  <result pre="and FriemanMBCD8+ T Cells and Macrophages Regulate Pathogenesis in a" exact="Mouse" post="Model of Middle East Respiratory Syndrome.J Virol201791110.1128/jvi.01825-16 53ZhaoJAlshukairiANBaharoonSAAhmedWABokhariAANehdiAMLayqahLAAlghamdiMGAl GethamyMMDadaAMKhalidIBoujelalMAl"/>
  <result pre="Macrophages Regulate Pathogenesis in a Mouse Model of Middle East" exact="Respiratory" post="Syndrome.J Virol201791110.1128/jvi.01825-16 53ZhaoJAlshukairiANBaharoonSAAhmedWABokhariAANehdiAMLayqahLAAlghamdiMGAl GethamyMMDadaAMKhalidIBoujelalMAl JohaniSMet al.Recovery from the Middle"/>
  <result pre="Syndrome.J Virol201791110.1128/jvi.01825-16 53ZhaoJAlshukairiANBaharoonSAAhmedWABokhariAANehdiAMLayqahLAAlghamdiMGAl GethamyMMDadaAMKhalidIBoujelalMAl JohaniSMet al.Recovery from the Middle East" exact="respiratory" post="syndrome is associated with antibody and T-cell responses.Sci Immunol2017214eaan539310.1126/sciimmunol.aan539328778905"/>
  <result pre="Virol201791110.1128/jvi.01825-16 53ZhaoJAlshukairiANBaharoonSAAhmedWABokhariAANehdiAMLayqahLAAlghamdiMGAl GethamyMMDadaAMKhalidIBoujelalMAl JohaniSMet al.Recovery from the Middle East respiratory" exact="syndrome" post="is associated with antibody and T-cell responses.Sci Immunol2017214eaan539310.1126/sciimmunol.aan539328778905 54MullerMAMeyerBCormanVMAl-MasriMTurkestaniARitzDSiebergAAldabbaghSBoschBJLattweinEAlhakeemRFAssiriAMAlbarrakAMet"/>
  <result pre="antibody and T-cell responses.Sci Immunol2017214eaan539310.1126/sciimmunol.aan539328778905 54MullerMAMeyerBCormanVMAl-MasriMTurkestaniARitzDSiebergAAldabbaghSBoschBJLattweinEAlhakeemRFAssiriAMAlbarrakAMet al.Presence of Middle East" exact="respiratory" post="syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional,"/>
  <result pre="and T-cell responses.Sci Immunol2017214eaan539310.1126/sciimmunol.aan539328778905 54MullerMAMeyerBCormanVMAl-MasriMTurkestaniARitzDSiebergAAldabbaghSBoschBJLattweinEAlhakeemRFAssiriAMAlbarrakAMet al.Presence of Middle East respiratory" exact="syndrome" post="coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological"/>
  <result pre="55KayaliGPeirisMA more detailed picture of the epidemiology of Middle East" exact="respiratory" post="syndrome coronavirus.Lancet Infect Dis201515549549710.1016/s1473-3099(15)70128-325863563 56Al KahloutRANasrallahGKFaragEAWangLLattweinEMullerMAEl ZowalatyMEAl RomaihiHEGrahamBSAl Thani"/>
  <result pre="more detailed picture of the epidemiology of Middle East respiratory" exact="syndrome" post="coronavirus.Lancet Infect Dis201515549549710.1016/s1473-3099(15)70128-325863563 56Al KahloutRANasrallahGKFaragEAWangLLattweinEMullerMAEl ZowalatyMEAl RomaihiHEGrahamBSAl Thani AA"/>
  <result pre="in Qatar.J Immunol Res20192019138674010.1155/2019/138674030906787 57KroemerGCuende E and MartinezCCompartmentalization of the" exact="peripheral" post="immune system.Adv Immunol19935315721610.1016/s0065-2776(08)60500-38512035 58Woodward DavisASRoozenHNDufortMJDeBergHADelaneyMAMairFEricksonJRSlichterCKBerksonJDKlockAMMackMLwoYKoAet al.The human tissue-resident CCR5(+)"/>
  <result pre="al.Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected" exact="Pneumonia" post="in Wuhan, China.JAMA.202010.1001/jama.2020.1585 61ZhangJJDongXCaoYYYuanYDYangYBYanYQAkdis CA and GaoYDClinical characteristics of"/>
  <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studies.Biosci Trends.202010.5582/bst.2020.01047 65TrombettaHFaggionHZLeotteJNogueiraMBVidal LR and RaboniSMHuman coronavirus"/>
  <result pre="clinical studies.Biosci Trends.202010.5582/bst.2020.01047 65TrombettaHFaggionHZLeotteJNogueiraMBVidal LR and RaboniSMHuman coronavirus and severe" exact="acute" post="respiratory infection in Southern Brazil.Pathog Glob Health2016110311311810.1080/20477724.2016.118129427195607 66GoesLGBZerbinatiRMTatenoAFde SouzaAVEbachFCormanVMMoreira-FilhoCADurigonELda"/>
  <result pre="studies.Biosci Trends.202010.5582/bst.2020.01047 65TrombettaHFaggionHZLeotteJNogueiraMBVidal LR and RaboniSMHuman coronavirus and severe acute" exact="respiratory" post="infection in Southern Brazil.Pathog Glob Health2016110311311810.1080/20477724.2016.118129427195607 66GoesLGBZerbinatiRMTatenoAFde SouzaAVEbachFCormanVMMoreira-FilhoCADurigonELda Silva"/>
  <result pre="Trends.202010.5582/bst.2020.01047 65TrombettaHFaggionHZLeotteJNogueiraMBVidal LR and RaboniSMHuman coronavirus and severe acute respiratory" exact="infection" post="in Southern Brazil.Pathog Glob Health2016110311311810.1080/20477724.2016.118129427195607 66GoesLGBZerbinatiRMTatenoAFde SouzaAVEbachFCormanVMMoreira-FilhoCADurigonELda Silva FilhoLDrexlerJFTypical"/>
  <result pre="Southern Brazil.Pathog Glob Health2016110311311810.1080/20477724.2016.118129427195607 66GoesLGBZerbinatiRMTatenoAFde SouzaAVEbachFCormanVMMoreira-FilhoCADurigonELda Silva FilhoLDrexlerJFTypical epidemiology of" exact="respiratory" post="virus infections in a Brazilian slum.J Med Virol.201910.1002/jmv.25636 67LauSKWooPCYipCCTseHTsoiHWChengVCLeePTangBSCheungCHLeeRASoLYLauYLChanKHet"/>
  <result pre="Glob Health2016110311311810.1080/20477724.2016.118129427195607 66GoesLGBZerbinatiRMTatenoAFde SouzaAVEbachFCormanVMMoreira-FilhoCADurigonELda Silva FilhoLDrexlerJFTypical epidemiology of respiratory virus" exact="infections" post="in a Brazilian slum.J Med Virol.201910.1002/jmv.25636 67LauSKWooPCYipCCTseHTsoiHWChengVCLeePTangBSCheungCHLeeRASoLYLauYLChanKHet al.Coronavirus HKU1"/>
  <result pre="SouzaAVEbachFCormanVMMoreira-FilhoCADurigonELda Silva FilhoLDrexlerJFTypical epidemiology of respiratory virus infections in a" exact="Brazilian" post="slum.J Med Virol.201910.1002/jmv.25636 67LauSKWooPCYipCCTseHTsoiHWChengVCLeePTangBSCheungCHLeeRASoLYLauYLChanKHet al.Coronavirus HKU1 and other coronavirus"/>
  <result pre="Brazilian slum.J Med Virol.201910.1002/jmv.25636 67LauSKWooPCYipCCTseHTsoiHWChengVCLeePTangBSCheungCHLeeRASoLYLauYLChanKHet al.Coronavirus HKU1 and other coronavirus" exact="infections" post="in Hong Kong.J Clin Microbiol20064462063207110.5353/th_b450106016757599 68OwusuMAnnanACormanVMLarbiRAntiPDrexlerJFAgbenyegaOAdu-Sarkodie Y and DrostenCHuman"/>
  <result pre="Kong.J Clin Microbiol20064462063207110.5353/th_b450106016757599 68OwusuMAnnanACormanVMLarbiRAntiPDrexlerJFAgbenyegaOAdu-Sarkodie Y and DrostenCHuman coronaviruses associated with" exact="upper" post="respiratory tract infections in three rural areas of Ghana.PLoS"/>
  <result pre="Clin Microbiol20064462063207110.5353/th_b450106016757599 68OwusuMAnnanACormanVMLarbiRAntiPDrexlerJFAgbenyegaOAdu-Sarkodie Y and DrostenCHuman coronaviruses associated with upper" exact="respiratory" post="tract infections in three rural areas of Ghana.PLoS One201497e9978210.1371/journal.pone.009978225080241"/>
  <result pre="68OwusuMAnnanACormanVMLarbiRAntiPDrexlerJFAgbenyegaOAdu-Sarkodie Y and DrostenCHuman coronaviruses associated with upper respiratory tract" exact="infections" post="in three rural areas of Ghana.PLoS One201497e9978210.1371/journal.pone.009978225080241 69ZhangSFTuoJLHuangXBZhuXZhangDMZhouKYuanLLuoHJZhengBJYuenKYLiMFCao KY"/>
  <result pre="KY and XuLEpidemiology characteristics of human coronaviruses in patients with" exact="respiratory" post="infection symptoms and phylogenetic analysis of HCoV-OC43 during 2010-2015"/>
  <result pre="and XuLEpidemiology characteristics of human coronaviruses in patients with respiratory" exact="infection" post="symptoms and phylogenetic analysis of HCoV-OC43 during 2010-2015 in"/>
  <result pre="229E, NL63, and HKU1: a study of hospitalized children with" exact="acute" post="respiratory tract infection in Guangzhou, China.Eur J Clin Microbiol"/>
  <result pre="NL63, and HKU1: a study of hospitalized children with acute" exact="respiratory" post="tract infection in Guangzhou, China.Eur J Clin Microbiol Infect"/>
  <result pre="HKU1: a study of hospitalized children with acute respiratory tract" exact="infection" post="in Guangzhou, China.Eur J Clin Microbiol Infect Dis201837236336910.1007/s10096-017-3144-z29214503 71SipulwaLAOngusJRColdren"/>
  <result pre="microbes present in the nasopharynx of children hospitalised with suspected" exact="pulmonary" post="tuberculosis in Cape Town, South Africa.BMC Infect Dis201616159710.1186/s12879-016-1934-z27776489 74SubramoneyKHellfersceeOPretoriusMTempiaSMcMorrowMvon"/>
  <result pre="present in the nasopharynx of children hospitalised with suspected pulmonary" exact="tuberculosis" post="in Cape Town, South Africa.BMC Infect Dis201616159710.1186/s12879-016-1934-z27776489 74SubramoneyKHellfersceeOPretoriusMTempiaSMcMorrowMvon GottbergAWolterNVariavaEDawoodHKahnKWalazaSMadhiSACohenCet"/>
  <result pre="bocavirus, coronavirus, and polyomavirus detected among patients hospitalised with severe" exact="acute" post="respiratory illness in South Africa, 2012 to 2013.Health Sci"/>
  <result pre="coronavirus, and polyomavirus detected among patients hospitalised with severe acute" exact="respiratory" post="illness in South Africa, 2012 to 2013.Health Sci Rep201818e5910.1002/hsr2.5930623094"/>
  <result pre="two polyomaviruses and four coronaviruses in HIV-infected and HIV-uninfected South" exact="African" post="children.PLoS One201492e8644810.1371/journal.pone.008644824498274 76KillerbyMEBiggsHMHaynesADahlRMMustaquimDGerber SI and WatsonJTHuman coronavirus circulation in"/>
  <result pre="â€&quot; angiotensin converting enzyme; ADE â€&quot; antibody-dependent enhancement; ARDS â€&quot;" exact="acute" post="respiratory distress syndrome; CoV â€&quot; coronavirus; COVID-19 â€&quot; coronavirus"/>
  <result pre="angiotensin converting enzyme; ADE â€&quot; antibody-dependent enhancement; ARDS â€&quot; acute" exact="respiratory" post="distress syndrome; CoV â€&quot; coronavirus; COVID-19 â€&quot; coronavirus disease"/>
  <result pre="acute respiratory distress syndrome; CoV â€&quot; coronavirus; COVID-19 â€&quot; coronavirus" exact="disease" post="2019; HCoV â€&quot; human coronavirus; MERS â€&quot; Middle-East respiratory"/>
  <result pre="coronavirus disease 2019; HCoV â€&quot; human coronavirus; MERS â€&quot; Middle-East" exact="respiratory" post="syndrome; SARI â€&quot; severe acute respiratory illness; SARS â€&quot;"/>
  <result pre="human coronavirus; MERS â€&quot; Middle-East respiratory syndrome; SARI â€&quot; severe" exact="acute" post="respiratory illness; SARS â€&quot; severe acute respiratory syndrome."/>
  <result pre="coronavirus; MERS â€&quot; Middle-East respiratory syndrome; SARI â€&quot; severe acute" exact="respiratory" post="illness; SARS â€&quot; severe acute respiratory syndrome."/>
  <result pre="syndrome; SARI â€&quot; severe acute respiratory illness; SARS â€&quot; severe" exact="acute" post="respiratory syndrome."/>
  <result pre="SARI â€&quot; severe acute respiratory illness; SARS â€&quot; severe acute" exact="respiratory" post="syndrome."/>
 </snippets>
</snippetsTree>
